Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, SGLT2i

JPM 2020 Day 4: Lexicon and Hanmi; Generic Jardiance Tentative Approval

Here is a brief preview of this blast: On the final day of JPM 2020, there was a single diabetes-related presentation from Lexicon, which highlighted the upcoming CDER decision on sotagliflozin in T1DM as well as the expansion of the SOLOIST-WHF trial to include non-T2DM patients. Furthermore, Hanmi's presentation at JPM was not webcast, but the company issued a press release with highlights of its obesity and NASH pipeline. Separately, FDA recently granted tentative approval to Alembic LTD for a generic version of BI/Lilly's Jardiance. Below, FENIX provides highlights and insights from the respective news items including additional insight and context from the ongoing litigation between BI and Alembic.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.